Treatment progress on castration-resistant prostate cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 766-769, 2016.
Article
in Zh
| WPRIM
| ID: wpr-503507
Responsible library:
WPRO
ABSTRACT
Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100%mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Clinical Oncology
Year:
2016
Type:
Article